CPIX - Company ID 0001087294
CUMBERLAND PHARMACEUTICALS INC trades as CPIX. In its fiscal 2025 annual report the company posted revenue of $44.52M, up 17.6% from the prior year and net income of -$2.84M. This page tracks CUMBERLAND PHARMACEUTICALS INC through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years CUMBERLAND PHARMACEUTICALS INC's revenue grew from $33.03M to $44.52M, a compound annual growth rate of 3.4%. Net profit margin compressed from -2.9% to -6.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| DEFM14A | - | 2026-05-26 |
| PREM14A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-05 |
| Major company event | 8-K | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Major company event | 8-K | 2026-04-23 |
| Insider trade | 4 | 2026-03-20 |
The largest companies sharing CUMBERLAND PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).
CUMBERLAND PHARMACEUTICALS INC reported revenue of $44.52M for fiscal year 2025, an increase of 17.6% year over year.
In its latest fiscal year CUMBERLAND PHARMACEUTICALS INC reported a net loss of $2.84M.